Biotest Pharmaceuticals names new chief executive

Jordan Siegel is promoted from chief financial officer

Jordan Siegel will become chief executive of Biotest Pharmaceuticals Corporation (BPC), a wholly owned subsidiary of Biotest AG of Dreieich, Germany, on 1 May.

BPC’s interim chief executive, Georg Floss, will return to Germany on 30 April to assume the role of global head of operations at Biotest AG.

Siegel has been BPC’s senior vice president, finance and chief financial officer since its inception in 2007.

BPC researches, develops and manufactures biotherapeutic products for immunology and haematology. The firm is a leader in the collection of source plasma and is currently involved in the development of plasma protein products in the field of Primary Immune Deficiency (PID) and various hyperimmune (IG) products. It owns and manages 12 plasmapherisis centres across the US and a manufacturing facility in Boca Raton, Florida.

You may also like

Pharmaceutical

Optimising process steps and performance with agitated Nutsche filter-dryers

Agitated Nutsche filter dryers (ANFD) streamline solid-liquid separation by performing filtration, dewatering, and drying in a single sealed vessel; an enormous boon in fine chemicals and pharmaceutical production
Design & Build

Cleanroom Technology launches global cleanroom awards

Introducing the Cleanroom Technology Awards, the global benchmark for cleanroom excellence
Sustainability

ACG Packaging Materials becomes first pharma packaging firm to join WEF Lighthouse Network

The company has joined the World Economic Forum’s Global Lighthouse Network after its Shirwal facility was named a Lighthouse site, making it the world’s first pharmaceutical packaging company to receive the recognition for smart, sustainable manufacturing
Pharmaceutical

testo Saveris 1 update automates environmental monitoring workflows for pharma compliance

New features include automated workflows for efficient environmental monitoring, approvals for secure and compliant changes, and more flexible control of webhooks, as well as further improvements in performance, transparency and usability
Regulatory

Hims & Hers backs down on oral GLP-1 copycat after FDA pressure

Facing threats of legal action from Wegovy manufacturer Novo Nordisk and an FDA probe, the health and wellness company has decided to abandon its plans to offer a GLP-1 copycat
Pharmaceutical

PharmNovo enhances its board ahead of Phase II development

The new board members bring complementary experience in drug development, clinical execution and partnering, supporting the company’s continued progress and dialogue with potential partners
Research & Development

AdvanCell partners with 48Hour Discovery on peptide-based lead-212 radiotherapeutic

The pair will develop a novel peptide-based Lead-212 radiotherapeutic targeting a gastrointestinal cancer with significant unmet need, strengthening AdcanCell's pipeline of differentiated targeted alpha therapies
Subscribe now